pD2 values and Emax to ranolazine in human saphenous rings precontracted with phenylephrine (10−7–10−6 M) in control and experimental conditions
| Ranolazine . | n . | pD2 . | Emax . |
|---|---|---|---|
| Control | 15 | 6.55 ± 0.26 | 94 ± 2 |
| l-NAME 10−4 M | 10 | 5.78 ± 0.18* | 90 ± 4 |
| Indomethacin 10−5 M | 5 | 5.98 ± 0.45 | 99 ± 1 |
| Indomethacin 10−5 M + l-NAME 10−4 M | 10 | 5.88 ± 0.17* | 88 ± 4 |
| Indomethacin 10−5 M + l-NAME 10−4 M + TEA 10−3 M | 5 | 4.89 ± 0.11*,† | 66 ± 7*,† |
| Indomethacin 10−5 M + l-NAME 10−4 M + charybdotoxin 10−7 M | 5 | 5.22 ± 0.43* | 73 ± 5*,† |
| Indomethacin 10−5 M + l-NAME 10−4 M + TRAM-34 10−6 M | 5 | 5.84 ± 0.08 | 89 ± 6 |
| Indomethacin 10−5 M + l-NAME 10−4 M + apamin 10−6 M | 6 | 5.60 ± 0.18 | 85 ± 8 |
| Ranolazine . | n . | pD2 . | Emax . |
|---|---|---|---|
| Control | 15 | 6.55 ± 0.26 | 94 ± 2 |
| l-NAME 10−4 M | 10 | 5.78 ± 0.18* | 90 ± 4 |
| Indomethacin 10−5 M | 5 | 5.98 ± 0.45 | 99 ± 1 |
| Indomethacin 10−5 M + l-NAME 10−4 M | 10 | 5.88 ± 0.17* | 88 ± 4 |
| Indomethacin 10−5 M + l-NAME 10−4 M + TEA 10−3 M | 5 | 4.89 ± 0.11*,† | 66 ± 7*,† |
| Indomethacin 10−5 M + l-NAME 10−4 M + charybdotoxin 10−7 M | 5 | 5.22 ± 0.43* | 73 ± 5*,† |
| Indomethacin 10−5 M + l-NAME 10−4 M + TRAM-34 10−6 M | 5 | 5.84 ± 0.08 | 89 ± 6 |
| Indomethacin 10−5 M + l-NAME 10−4 M + apamin 10−6 M | 6 | 5.60 ± 0.18 | 85 ± 8 |
Data are shown as mean ± SEM. Emax are expressed as a percentage of response to 60 mM KCl.
P < 0.05 versus control.
P < 0.05 versus indomethacin 10−5 M + l-NAME 10−4 M.
Emax: maximum effect; l-NAME: NG-nitro-l-arginine methyl ester; n: number of patients; pD2: −log EC50; SEM: standard error of mean; TEA: tetraethylammonium.
pD2 values and Emax to ranolazine in human saphenous rings precontracted with phenylephrine (10−7–10−6 M) in control and experimental conditions
| Ranolazine . | n . | pD2 . | Emax . |
|---|---|---|---|
| Control | 15 | 6.55 ± 0.26 | 94 ± 2 |
| l-NAME 10−4 M | 10 | 5.78 ± 0.18* | 90 ± 4 |
| Indomethacin 10−5 M | 5 | 5.98 ± 0.45 | 99 ± 1 |
| Indomethacin 10−5 M + l-NAME 10−4 M | 10 | 5.88 ± 0.17* | 88 ± 4 |
| Indomethacin 10−5 M + l-NAME 10−4 M + TEA 10−3 M | 5 | 4.89 ± 0.11*,† | 66 ± 7*,† |
| Indomethacin 10−5 M + l-NAME 10−4 M + charybdotoxin 10−7 M | 5 | 5.22 ± 0.43* | 73 ± 5*,† |
| Indomethacin 10−5 M + l-NAME 10−4 M + TRAM-34 10−6 M | 5 | 5.84 ± 0.08 | 89 ± 6 |
| Indomethacin 10−5 M + l-NAME 10−4 M + apamin 10−6 M | 6 | 5.60 ± 0.18 | 85 ± 8 |
| Ranolazine . | n . | pD2 . | Emax . |
|---|---|---|---|
| Control | 15 | 6.55 ± 0.26 | 94 ± 2 |
| l-NAME 10−4 M | 10 | 5.78 ± 0.18* | 90 ± 4 |
| Indomethacin 10−5 M | 5 | 5.98 ± 0.45 | 99 ± 1 |
| Indomethacin 10−5 M + l-NAME 10−4 M | 10 | 5.88 ± 0.17* | 88 ± 4 |
| Indomethacin 10−5 M + l-NAME 10−4 M + TEA 10−3 M | 5 | 4.89 ± 0.11*,† | 66 ± 7*,† |
| Indomethacin 10−5 M + l-NAME 10−4 M + charybdotoxin 10−7 M | 5 | 5.22 ± 0.43* | 73 ± 5*,† |
| Indomethacin 10−5 M + l-NAME 10−4 M + TRAM-34 10−6 M | 5 | 5.84 ± 0.08 | 89 ± 6 |
| Indomethacin 10−5 M + l-NAME 10−4 M + apamin 10−6 M | 6 | 5.60 ± 0.18 | 85 ± 8 |
Data are shown as mean ± SEM. Emax are expressed as a percentage of response to 60 mM KCl.
P < 0.05 versus control.
P < 0.05 versus indomethacin 10−5 M + l-NAME 10−4 M.
Emax: maximum effect; l-NAME: NG-nitro-l-arginine methyl ester; n: number of patients; pD2: −log EC50; SEM: standard error of mean; TEA: tetraethylammonium.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
